Bicara Therapeutics

Bicara Therapeutics has appointed Ryan Cohlhepp as CEO effective January 1, 2027; Dr. Claire Mazumdar will move into the role of vice chair and strategic advisor. Jenn Larson has been named CFO with immediate effect; additional management changes affect COO, CDO and business roles, and Greg Shiferman will join as chief legal officer effective August 31, 2026. The company reports progress in the regulatory FORTIFI-HN01 study for ficerafusp alfa and expects topline data from an interim analysis in mid-2027; the FORTIFI-FLEX study has also been initiated. In Q2 2026 Bicara posted a net loss of $55.4 million (prior year: $27.4 million) driven by higher R&D spending; cash and cash equivalents were $497.3 million as of June 30, 2026, which the company says funds operations through the first half of 2029. » Plus sur de.investing.com

Shares of Bicara Therapeutics rose to a new all-time high of $29.92, close to their 52-week high, up 221.6% year to date. The company reported expanded follow-up data on ficerafusp alfa plus pembrolizumab showing an estimated 3-year survival rate of about 31% at a 1500 mg dose. Analysts reiterated ratings: Citizens maintains "Market Outperform" with a $31.00 price target, Cantor Fitzgerald reaffirmed "Overweight", while InvestingPro flagged potential overvaluation and an overbought RSI. » Plus sur de.investing.com

Extended follow‑up data from a phase 1/1b study show that with a weekly dose of 1500 mg Ficerafusp alfa combined with pembrolizumab, an estimated 31% of patients with recurrent/metastatic HPV‑negative squamous cell carcinoma of the head and neck survived at three years. The study of about 90 patients also showed varying response and overall response rates across the three dose cohorts; median progression‑free survival ranged from 6.9 to 12.7 months. Bicara plans a phase 3 continuation (FORTIFI‑HN01) with 1500 mg weekly and intends to start a study with a different dosing regimen in Q3 2026; the FDA has granted the combination Breakthrough Therapy designation. Investors reacted positively to the data, with the stock trading near its 52‑week high, while a fair‑value analysis suggests possible overvaluation. » Plus sur de.investing.com